Oncternal Therapeutics (ONCT) Earnings Date, Estimates & Call Transcripts $0.53 0.00 (0.00%) As of 04/14/2025 Add Compare Share Share Earnings Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock Oncternal Therapeutics Earnings Summary Latest Q2 Earnings DateAug. 8EstimatedConsensus EPS (Aug. 8) -$3.03 Actual EPS (Aug. 8) -$2.89 Beat By $0.14 Actual Revenue (Aug. 8) $0.80MOncternal Therapeutics issued Q2 2024 earnings on August 8, 2024, reporting an EPS of -$2.89, which topped analysts' consensus estimates of -$3.03 by $0.14. Quarterly revenue was reported to be $0.80 million, above analyst estimates of $0.24 million. With a trailing EPS of -$11.69, Oncternal Therapeutics' earnings are expected to grow next year, from ($12.43) to ($10.25) per share. Q2 2024 Earnings ResourcesQ2 2024 Earnings ReportConference Call Transcript & Audio Quarterly Report (10-Q) Press Release (8-K)Powered by Get Oncternal Therapeutics Earnings Alerts Want to stay updated on the latest earnings announcements and upcoming reports? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Oncternal Therapeutics and other key companies, straight to your inbox. Enter your email to sign up for newsletter Sign Up Skip Charts & View Estimated and Actual Earnings DataONCT Earnings Estimates and Actuals by QuarterEarnings Estimates and Acutals by Quarter Chart DescriptionThe chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.ONCT Estimated and Actual Revenue by QuarterEstimated Revenue and Actual Revenue by Quarter Chart DescriptionThe chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter. Remove Ads Oncternal Therapeutics Analyst EPS EstimatesQuarterNumber of EstimatesLow EstimateHigh EstimateAverage EstimateQ1 20251-$2.42-$2.42-$2.42Q2 20251-$2.19-$2.19-$2.19Q3 20251-$2.00-$2.00-$2.00Q4 20251-$2.05-$2.05-$2.05FY 20254($8.66)($8.66)($8.66) Remove Ads Oncternal Therapeutics Earnings History by Quarter Custom Range 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 5 Years 10 Years Time Frame * Start Date * End Date Export to Excel DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueDetails8/8/2024Q2 2024-$3.03-$2.89+$0.14-$2.89$0.24M$0.80M5/9/2024Q1 2024-$2.88-$2.83+$0.05-$2.83$0.18M$0.57M3/7/2024Q4 2023-$3.09-$3.11 -$0.02-$3.11$0.17M$0.30M11/9/2023Q3 2023-$3.00-$3.40 -$0.40-$0.17$0.17M$0.18M8/10/2023Q2 2023-$3.40-$3.00+$0.40-$0.15$0.21M$0.11M5/4/2023Q1 2023-$4.20-$4.00+$0.20-$0.20$0.20M$0.20M Oncternal Therapeutics Earnings - Frequently Asked Questions When did Oncternal Therapeutics announce their last quarterly earnings? Oncternal Therapeutics (NASDAQ:ONCT) last announced its quarterly earning data on Thursday, August 8, 2024. Learn more on ONCT's earnings history. Did Oncternal Therapeutics beat their earnings estimates last quarter? In the previous quarter, Oncternal Therapeutics (NASDAQ:ONCT) reported ($2.89) earnings per share (EPS) to beat the analysts' consensus estimate of ($3.03) by $0.14. Learn more on analysts' earnings estimate vs. ONCT's actual earnings. How can I listen to Oncternal Therapeutics's earnings conference call? The conference call for Oncternal Therapeutics's latest earnings report can be listened to online. Listen to Conference Call How can I read Oncternal Therapeutics's conference call transcript? The conference call transcript for Oncternal Therapeutics's latest earnings report can be read online. Read Transcript How much revenue does Oncternal Therapeutics generate each year? Oncternal Therapeutics (NASDAQ:ONCT) has a recorded annual revenue of $790,000.00. How much profit does Oncternal Therapeutics generate each year? Oncternal Therapeutics (NASDAQ:ONCT) has a recorded net income of -$39.48 million. ONCT has generated -$11.69 earnings per share over the last four quarters. What is Oncternal Therapeutics's EPS forecast for next year? Oncternal Therapeutics's earnings are expected to grow from ($12.43) per share to ($10.25) per share in the next year. More Earnings Resources from MarketBeat Related Companies Aytu BioPharma Earnings Date Alzamend Neuro Earnings Date Lipella Pharmaceuticals Earnings Date TransCode Therapeutics Earnings Date GT Biopharma Earnings Date Portage Biotech Earnings Date Hoth Therapeutics Earnings Date Dogwood Therapeutics Earnings Date Phio Pharmaceuticals Earnings Date BioXcel Therapeutics Earnings Date Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Why Analysts Boosted United Airlines Stock Ahead of EarningsLamb Weston Stock Rises, Earnings Provide Calm Amidst ChaosIntuitive Machines Gains After Earnings Beat, NASA Missions AheadCintas Delivers Earnings Beat, Signals More Growth AheadNike Stock Dips on Earnings: Analysts Weigh in on What’s NextAfter Massive Post Earnings Fall, Does Hope Remain for MongoDB?Semtech Rallies on Earnings Beat—Is There More Upside? Remove Ads This page (NASDAQ:ONCT) was last updated on 4/16/2025 by MarketBeat.com Staff From Our PartnersTwo Unmistakable Patterns Return…The signs suggest we're entering one of those rare periods now. That's why Central Banks are buying gold at...Golden Portfolio | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredCrypto’s crashing…but we’re still profitingMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | SponsoredIs it CRAZY to still want reliable profits, despite this market?Larry Benedict, the acclaimed "Market Wizard," is calling an emergency briefing now... The same Larry who –...Brownstone Research | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredTariffs. Volatility. Fear. Here’s the Plan.Wall Street's panicking over tariffs. Volatility's back with a vengeance. If you've been glued to the he...Investors Alley | SponsoredThis story is about to go viralThis Story Could Go Viral as Soon as May 31 Quietly, towns like Shreveport, Louisiana and Fort Worth, Texas...Stansberry Research | SponsoredHow War with China Could Start in 128 DaysThe clock is ticking. Those who aren't prepared could lose everything. I've identified 43 investments we...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Oncternal Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Oncternal Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy ONCT Stock Free ONCT Stock Alerts